ATHE:NSD-Alterity Therapeutics Limited (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.76

Change

0.00 (0.00)%

Market Cap

USD 0.03B

Volume

0.50M

Avg Analyst Target

USD 4.00 (+423.70%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Alterity Therapeutics Limited (ATHE) Stock Analysis:
Based on the Alterity Therapeutics Limited stock forecasts from 1 analysts, the average analyst target price for Alterity Therapeutics Limited is USD 4.00 over the next 12 months. Alterity Therapeutics Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alterity Therapeutics Limited is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Alterity Therapeutics Limited’s stock price was USD 0.76. Alterity Therapeutics Limited’s stock price has changed by -0.05% over the past week, -0.06% over the past month and -59.80% over the last year.

About

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD67.92B 10.04 12.33
REGN Regeneron Pharmaceuticals Inc

N/A

USD66.83B 9.94 8.23
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD57.99B 27.35 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD35.77B 4.66 5.67
BGNE BeiGene Ltd

N/A

USD25.75B N/A N/A
SGEN Seagen Inc

N/A

USD23.32B 55.02 44.86
GMAB Genmab A/S

N/A

USD22.58B 51.93 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
RPRX Royalty Pharma plc

N/A

USD16.81B 20.32 11.89

ETFs Containing ATHE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.08% 96% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.08% 96% A 95% A
Trailing 12 Months  
Capital Gain -59.80% 43% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.80% 43% F 20% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 26.50% 64% D 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.50% 63% D 73% C
Risk Return Profile  
Volatility (Standard Deviation) 69.37% 42% F 23% F
Risk Adjusted Return 38.20% 69% D+ 57% F
Market Capitalization 0.03B 12% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 97% A+ 97% A+
Price/Book Ratio 1.69 75% C 62% D-
Price / Cash Flow Ratio -2.00 26% F 60% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -81.39% 35% F 14% F
Return on Invested Capital -78.35% 27% F 11% F
Return on Assets -46.50% 15% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.47 71% C- 65% D
Short Percent 2.25% 71% C- 54% F
Beta 0.94 65% D 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.